Dopaminergic neurons of the substantia nigra pars compacta (SNpc) are impacted by Parkinson's disease (PD), a multisystem condition that causes a decrease in dopamine (DA) at their striatal terminals. Levodopa or DA receptor agonists are used to treat Parkinson's disease because they replace the role of diminished DA in the striatum. Extended use of these medications for treatment has variable therapeutic outcomes and may cause undesirable dyskinesia. Therefore, a crucial unmet need in the treatment of Parkinson's disease is to develop novel methods to slow down, stop, or reverse the process of neurodegeneration. Researchers are looking into natural substances with neuroprotective characteristics as potential treatments. A polyphenolic compound called curcumin is obtained from the rhizomes of Curcuma longa (turmeric). As a potential therapeutic and nutraceutical agent for the treatment of Parkinson's disease, it has been demonstrated to possess potent anti-inflammatory, antioxidant, free radical scavenging, mitochondrial protecting, iron-chelating, and MAO inhibitory effects.
Author (s) Details
Eslam El Nebrisi
Department of Pharmacology, Dubai Medical
College, Dubai 20170, United Arab Emirates.
View Book :- https://stm.bookpi.org/CPMS-V6/article/view/7685
No comments:
Post a Comment